1. Epidemiology and Global Health
  2. Medicine

Risk of heart disease following treatment for breast cancer – results from a population-based cohort study

  1. Haomin Yang  Is a corresponding author
  2. Nirmala Bhoo-Pathy
  3. Judith S Brand
  4. Elham Hedayati
  5. Felix Grassmann
  6. Erwei Zeng
  7. Jonas Bergh
  8. Weiwei Bian
  9. Jonas F Ludvigsson
  10. Per Hall
  11. Kamila Czene
  1. Department of Epidemiology and Health Statistics, School of Public Health, Fujian Medical University, China
  2. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Sweden
  3. Centre for Epidemiology and Evidence-Based Practice, Faculty of Medicine, University of Malaya, Malaysia
  4. Clinical Epidemiology and Biostatistics, School of Medical Sciences, Örebro University, Sweden
  5. Department of Oncology-Pathology, Karolinska Institutet, Sweden
  6. Health and Medical University, Germany
  7. Breast Cancer Center, Karolinska University Hospital, Sweden
  8. Karolinska Comprehensive Cancer Center, Sweden
  9. Department of Pediatrics, Örebro University Hospital, Sweden
  10. Department of Oncology, Södersjukhuset, Sweden
https://doi.org/10.7554/eLife.71562
Share this article
Cite this article
  1. Haomin Yang
  2. Nirmala Bhoo-Pathy
  3. Judith S Brand
  4. Elham Hedayati
  5. Felix Grassmann
  6. Erwei Zeng
  7. Jonas Bergh
  8. Weiwei Bian
  9. Jonas F Ludvigsson
  10. Per Hall
  11. Kamila Czene
(2022)
Risk of heart disease following treatment for breast cancer – results from a population-based cohort study
eLife 11:e71562.
https://doi.org/10.7554/eLife.71562
  2. Download BibTeX
  3. Download .RIS

Abstract

Background:

There is a rising concern about treatment-associated cardiotoxicities in breast cancer patients. This study aimed to determine the time- and treatment-specific incidence of arrhythmia, heart failure, and ischemic heart disease in women diagnosed with breast cancer.

Methods:

A register-based matched cohort study was conducted including 8015 breast cancer patients diagnosed from 2001 to 2008 in the Stockholm-Gotland region and followed up until 2017. Time-dependent risks of arrhythmia, heart failure, and ischemic heart disease in breast cancer patients were assessed using flexible parametric models as compared to matched controls from general population. Treatment-specific effects were estimated in breast cancer patients using Cox model.

Results:

Time-dependent analyses revealed long-term increased risks of arrhythmia and heart failure following breast cancer diagnosis. Hazard ratios (HRs) within the first year of diagnosis were 2.14 (95% CI = 1.63–2.81) for arrhythmia and 2.71 (95% CI = 1.70–4.33) for heart failure. HR more than 10 years following diagnosis was 1.42 (95% CI = 1.21–1.67) for arrhythmia and 1.28 (95% CI = 1.03–1.59) for heart failure. The risk for ischemic heart disease was significantly increased only during the first year after diagnosis (HR = 1.45, 95% CI = 1.03–2.04). Trastuzumab and anthracyclines were associated with increased risk of heart failure. Aromatase inhibitors, but not tamoxifen, were associated with risk of ischemic heart disease. No increased risk of heart disease was identified following locoregional radiotherapy.

Conclusions:

Administration of systemic adjuvant therapies appears to be associated with increased risks of heart disease. The risk estimates observed in this study may aid adjuvant therapy decision-making and patient counseling in oncology practices.

Funding:

This work was supported by the Swedish Research Council (grant no: 2018-02547); Swedish Cancer Society (grant no: CAN-19-0266); and FORTE (grant no: 2016-00081).

Editor's evaluation

We feel that your work will be of interest to breast medical oncologists, cardiologists, and primary care providers who treat patients with breast cancer. We commend you for this study, which achieves its goal of identifying the incidence and hazard ratio of cardio-toxicity associated with breast cancer treatment within a general breast cancer population. The international nature of your collaborative study along with its large patient cohort size and long horizontal follow up are quite attractive features in solidifying previous findings and discovering future areas of exploration.

https://doi.org/10.7554/eLife.71562.sa0

Introduction

The use of adjuvant systemic therapies at least halves the risk of dying from breast cancer (Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), 2005; Dowsett et al., 2015; Goldvaser et al., 2019; Gray et al., 2019). Nowadays, 80% of the breast cancer patients survive for at least 10 years and many will become long-term survivors. There are, however, concerns about therapy-associated late adverse health effects, including cardiovascular events (Khouri et al., 2012). Use of common (neo-)adjuvant therapies for breast cancer has been associated with an increased risk of heart diseases including heart failure, arrhythmias, and ischemic heart disease (Darby et al., 2013; Doyle et al., 2005; Harris et al., 2006; Hooning et al., 2007; Pinder et al., 2007; Taylor et al., 2017; Yeh and Bickford, 2009). However, this evidence mostly comes from studies focusing on specific subgroups of patients based on age, cancer stage, or treatment regimen.

Although the benefits of radiotherapy far outweigh the risk of heart diseases, some studies have found increased incidence of and mortality due to heart disease in women subjected to radiotherapy techniques (Darby et al., 2013; Taylor et al., 2017). Knowledge on cardiotoxic effects of anthracycline-based chemotherapy regimens have led to lowering of doses and less use of bolus injections to reduce peak concentrations of anthracyclines (Foukakis et al., 2016), but it is estimated that the risk of heart failure associated with anthracyclines remains increased for standard low-dose group as compared to non-users (Chung et al., 2020). While trastuzumab has been shown to reduce the risk of breast cancer mortality at 11 years of follow-up (Cameron et al., 2017), evidence on its cardiotoxicity is conflicting (Bowles et al., 2012; Papakonstantinou et al., 2020). In addition, recent evidence suggests that use of aromatase inhibitors in women with hormone receptor positive breast cancer may increase the risk of heart failure, compared to tamoxifen (Khosrow-Khavar et al., 2020).

Risk assessment of immediate and later occurring heart disease events following breast cancer is important for the planning of cardiac surveillance programs and possible prophylactic pharmacotherapy. Here, we report the risks of heart diseases in a cohort representative of the general breast cancer population with long-term follow-up. We specifically aimed to assess risks of heart diseases by time since diagnosis, and according to adjuvant treatments.

Materials and methods

Breast cancer cohort

Request a detailed protocol

This study took advantage of the Stockholm-Gotland Breast Cancer Register comprising all women diagnosed with primary invasive breast cancer between 2001 and 2008 in the Stockholm-Gotland region. The Stockholm-Gotland Breast Cancer Register has about 99% completeness and provides detailed information on tumor and treatment characteristics, as well as routine follow-up on locoregional recurrences and distant metastases (Colzani et al., 2011; Wigertz et al., 2012). Detailed description of the breast cancer cohort can be found elsewhere (Holm et al., 2016). We included all patients diagnosed with non-metastatic breast cancer (stages I–III) and without prior diagnosis of heart disease at age 25–75 years (N = 8015). To compare the risk of heart diseases after breast cancer diagnosis, we randomly sampled up to 10 women from the general female population in Stockholm-Gotland region matched on year of birth (Appendix 1—figure 1). Each reference individual was alive and free of breast cancer on the date of the matched patient’s diagnosis of breast cancer (the index date).

The matched cohort was linked through the unique personal identity number to the Swedish Cancer Register, Patient Register, Cause of Death Register and Migration Register, and follow-up started from the index date until the date of heart disease diagnosis, emigration, death, breast cancer relapse, or end of follow-up (December 31, 2017), whichever occurred first. We also performed linkage with the Prescribed Drug Register which contains data on all drugs dispensed from Swedish pharmacies from July 2005 onward to validate the use of hormone therapy.

The study was approved by the Regional Ethical Review Board in Stockholm.

Heart diseases

Request a detailed protocol

We identified the following heart diseases according to relevant ICD (International Classification of Disease) codes in the Swedish Patient Register and the Cause of Death Register (Appendix 2—table 1): heart failure (ICD-10: I50, ICD-9: 428A, 428B, 428X), arrhythmias (ICD-10: I47–I49, ICD-9: 427), and ischemic heart disease (ICD-10: I20–I25, ICD-9: 410–414). We included both inpatient and outpatient diagnoses, as well as cause of death records in our outcome definition, except for myocardial infarction, which was based on inpatient and cause of death records solely. To ensure specificity of the outcomes studied, only primary, and not underlying, diagnoses were considered for analyses.

Breast cancer treatment specifics

Request a detailed protocol

We extracted the treatment data from the Stockholm-Gotland Breast Cancer Register. As ~90% of HER-2 positive cancers were treated with trastuzumab between 2005 and 2008 in the Stockholm-Gotland region and the Swedish Prescribed Drug Register does not cover data on treatment with trastuzumab, HER-2 positivity was used as a proxy when no registry data on trastuzumab was available during this time period (30% of the HER-2 positive patients had missing information on trastuzumab). Data on adjuvant endocrine therapy was verified against the Prescribed Drug Register and categorized into tamoxifen and/or aromatase inhibitor use. Since radiotherapy to the left breast has, in particular, been implicated in heart complications, radiotherapy was categorized according to tumor laterality (left vs. right). Bilateral tumors were coded separately in this analysis. Chemotherapy was coded as anthracycline-based, anthracycline plus taxane-based, cyclophosphamide, methotrexate, and fluorouracil (CMF)-based regimens.

Covariates

Request a detailed protocol

The Stockholm Breast Cancer Register contains data on date of diagnosis, menopausal status at diagnosis, and type of surgery (breast conserving surgery vs. mastectomy). Tumor characteristics were also retrieved from this register, including tumor size (T), regional lymph node involvement (N), and presence of metastases (M), all from pathology records and summarized in TNM stage as defined according to the American Joint Committee on Cancer, 2010. Information on inpatient comorbidities at diagnosis was extracted through the Swedish Patient Register and summarized into the Charlson comorbidity index (CCI) score, a widely used method for classifying chronic comorbid conditions (Charlson et al., 1987). To account for the potential confounding effect from tobacco abuse, chronic pulmonary disease, and hypertension in the associations, we further identified associated diagnoses before cancer using ICD codes from the patient register (Appendix 2—table 1).

Statistical analyses

Request a detailed protocol

We compared the risk of heart diseases in breast cancer patients with that observed in the matched cohort, using flexible parametric model (FPM) with time since index date as underlying time scale. The FPM is similar to the Cox proportional hazards model in that it provides a hazard ratio (HR) as measure of association. In our analysis, a restricted cubic spline with four internal and two boundary knots (five degrees of freedom) placed at quintiles of the event times was used in the FPM for the baseline hazard. The key advantage of FPM is that non-proportional hazards can easily be fitted by adding a second spline for the interaction with time. Considering the correlation within the matched clusters, a shared frailty term (as random effects) was incorporated into the model and the maximum (penalized) marginal likelihood method was used to estimate the regression coefficients and the variance for the frailty. Aalen-Johansen estimation was used to assess the cumulative incidences of heart diseases in breast cancer patients and matched reference individuals, while other causes of death were considered as competing events.

Next, we studied the association of adjuvant breast cancer therapy with heart disease risk in breast cancer patients using Cox proportional hazards models. We adjusted these analyses for age and year of diagnosis (model 1), and additionally for menopausal status at diagnosis, cancer stage, type of surgery, CCI score, hypertension, chronic pulmonary disease, and tobacco abuse. All treatment-specific models were mutually adjusted for adjuvant therapies. Considering the possible selection bias in the administration of radiotherapy (Wadsten et al., 2018), the analysis for radiotherapy only included patients receiving radiotherapy, making a comparison between left-sided, right-sided, and both-sided breast cancer. Multiple imputation with chained equations was used to deal with the treatment categories with missing information. We replaced the missing data with 10 rounds of imputations and all the covariates were included in the imputation model. Considering the time-dependent effect of treatment, we separated the analysis according to different follow-up periods, within 10 years after breast cancer diagnosis and beyond, respectively.

All statistical analyses were performed using STATA version 15.1.

Results

Descriptive characteristics of the study population are described in Table 1. The median age at breast cancer diagnosis was 59 years, with 74.3% of patients aged less than 65 years (Table 1). Approximately 40% of all patients received adjuvant chemotherapy, with anthracyline-based regimens being most frequently administered. Endocrine therapy was received by more than 80% of patients (constituting mainly of tamoxifen). Of all patients diagnosed between mid-2005 and 2008, 13% were coded as receivers of trastuzumab.

Table 1
Descriptive characteristics of the study population.
CharacteristicsOverall (N = 8015)
Year of diagnosis % (N)
2001–200225.6 (2072)
2003–200424.4 (1952)
2005–200625.8 (2064)
2007–200824.0 (1927)
Age at diagnosis % (N)
<50 years23.0 (1842)
50–65 years51.3 (4111)
>65 years25.7 (2062)
Menopausal status % (N)
Premenopausal30.4 (2289)
Postmenopausal69.6 (5251)
Missing (N)475
Stage % (N)
Stage I48.2 (3690)
Stage II39.4 (3014)
Stage III12.4 (948)
Missing (N)363
Tumor size % (N)
≤2 cm25.7 (2000)
2–5 cm44.0 (3418)
> 5 cm30.3 (2351)
Missing (N)246
Comorbidity % (N)
None90.1 (7222)
15.5 (439)
≥24.4 (354)
History of hypertension
No94.6 (7579)
Yes5.4 (436)
History of chronic pulmonary disease or tobacco abuse
No96.6 (7746)
Yes3.4 (269)
Surgery % (N)
No1.0 (79)
Yes, breast-conserving60.7 (4852)
Yes, mastectomy38.3 (3058)
Missing (N)26
Radiotherapy % (N)
No22.5 (1774)
Yes, left-sided37.5 (2962)
Yes, right-sided39.1 (3088)
Yes, both-sided0.85 (67)
Missing (N)124
Chemotherapy % (N)
No58.5 (4604)
Yes41.5 (3262)
Missing (N)149
Hormone therapy % (N)
No18.10 (1424)
Yes, tamoxifen53.0 (4247)
Yes, aromatase inhibitors19.3 (1550)
Yes, type unknown8.1 (645)
Missing (N)149
Trastuzumab therapy % (N) *
No87.3 (2180)
Yes12.7 (316)
Missing (N)1497
  1. *

    Missingness on individual variables is less than 5%, except for menopausal status (5.9%, N = 488). Treatment-specific analysis of trastuzumab was restricted to patients diagnosed between 2005 and 2008 (missingness = 37.5%, N = 1497).

Over a median follow-up of 10.8 years (interquartile range = 6.5 years), arrhythmias were the most frequently reported heart disease (n = 570), followed by ischemic heart disease (n = 307) and heart failure (n = 243). The cumulative incidence of arrhythmias, ischemic heart disease, and heart failure in the breast cancer patients cohort was 11.0%, 5.7%, and 4.8% after 15 years of follow-up, while the cumulative incidence was 8.2%, 5.9%, and 3.8% in the matched cohort, respectively (Appendix 2—table 2 and Appendix 3—figure 1).

Figure 1 shows the time-dependent risks of heart diseases in breast cancer patients compared to the reference population. A short-term increase in risks of arrhythmia and heart failure was found in breast cancer patients (Table 2, Figure 1, HR at first year for arrhythmia = 2.14; 95% CI = 1.63–2.81, for heart failure = 2.71; 95% CI = 1.70–4.33, respectively). An elevated risk of ischemic heart disease was also observed in the first year after diagnosis (HR = 1.45; 95% CI = 1.03–2.04), followed by a decline with increasing follow-up time. Interestingly, increased risks for arrhythmia and heart failure were noted beyond 10 years (Table 2, Figure 1, HR for arrhythmia = 1.42; 95% CI = 1.21–1.67; HR for heart failure = 1.28; 95% CI = 1.03–1.59).

Figure 1
Download asset Open asset
Time-dependent hazard ratio of heart diseases in breast cancer patients compared to age-matched women.

In all models, time since index date was the underlying time scale and a restricted cubic spline with four internal and two boundary knots (five degrees of freedom) placed at quintiles of the event times was used for the baseline hazard. Time-dependent effects were modelled by adding interaction terms with time using a second spline with three degrees of freedom.

Figure 1—source data 1

Summary data for Figure 1.

https://cdn.elifesciences.org/articles/71562/elife-71562-fig1-data1-v2.xlsx
Table 2
Hazard ratios for heart diseases in breast cancer patients compared to the matched cohort.
ArrhythmiaHeart failureIschemic heart disease
No.HR (95% CI)No.HR (95% CI)No.HR (95% CI)
Time since diagnosis
<1 year642.14 (1.63–2.81)222.71 (1.70–4.33)381.45 (1.03–2.04)
1–2 years341.08 (0.76–1.53)192.07 (1.27–3.37)341.12 (0.79–1.61)
2–5 years1071.07 (0.88–1.30)381.14 (0.82–1.59)720.84 (0.66–1.07)
5–10 years2041.13 (0.98–1.30)781.02 (0.81–1.29)1040.82 (0.67–1.00)
10–17 years1611.42 (1.21–1.67)861.28 (1.03–1.59)590.79 (0.61–1.03)

  1. Abbreviations: No. = number of cases. HR = hazard ratio. CI = confidence interval. The HRs are estimated using flexible parametric model and conditioned on matching criteria (year of birth). In all models, time since index date was the underlying time scale and a restricted cubic spline with four internal and two boundary knots (five degrees of freedom) placed at quintiles of the event times was used for the baseline hazard. All analyses were stratified by time since index date. Statistically significant results with p-value<0.05 are bolded.

Table 3 presents the HRs in breast cancer patients by adjuvant therapy. Patients treated with chemotherapy and trastuzumab had an increased risk of heart failure compared to patients not receiving these treatments (for patients receiving anthracyclines-based chemotherapy, HR = 1.74, 95% CI = 1.20–2.52; for patients receiving trastuzumab, HR = 2.34, 95% CI = 1.05–5.22) (Table 3). The risk of heart failure in patients receiving anthracyclines potentially persisted for 10 years beyond the diagnosis of breast cancer (HR = 1.66, 95% CI = 0.86–3.19, Appendix 2—table 3). Receipt of aromatase inhibitors was associated with risk of ischemic heart disease (HR = 1.52, 95% CI = 1.03–2.26 compared to patients without hormonal therapy), but not with risk of heart failure or arrhythmias (Table 3). A direct comparison between left-sided and right-sided radiotherapy showed no evidence of an association of radiotherapy with heart disease except for a somewhat increased risk of ischemic heart disease in women with left-sided breast cancer, particularly after 10 years after cancer diagnosis, although not statistically significant (Appendix 2—table 3, HR = 1.16, 95% CI = 0.89–1.51; HR for the risk beyond 10 years = 1.29, 95% CI = 0.70–2.37).

Table 3
Hazard ratios for heart diseases in breast cancer patients by different adjuvant therapies.
Total No.HR (95% CI) for arrhythmiaHR (95% CI) for heart failureHR (95% CI) for ischemic heart disease
Treatment variablesNModel 1Model 2NModel 1Model 2NModel 1Model 2
Radiotherapy
Right-sided2948216REF (1.00)REF (1.00)80REF (1.00)REF (1.00)99REF (1.00)REF (1.00)
Left-sided30752130.93 (0.77–1.13)0.93 (0.77–1.13)871.03 (0.76–1.40)1.07 (0.79–1.45)1191.14 (0.87–1.49)1.16 (0.89–1.51)
Both-sided6740.65 (0.24–1.76)0.63 (0.23–1.70)41.81 (0.66–4.95)1.75 (0.63–4.85)31.08 (0.34–3.40)0.98 (0.31–3.11)
Chemotherapy
No.4604376REF (1.00)REF (1.00)133REF (1.00)REF (1.00)207REF (1.00)REF (1.00)
Anthracyclines-based1426831.18 (0.97–1.45)1.08 (0.84–1.39)512.30 (1.70–3.10)1.74 (1.20–2.52)441.31 (0.99–1.72)1.29 (0.92–1.81)
Anthracyclines + taxanes286101.15 (0.63–2.10)1.01 (0.53–1.92)134.71 (2.57–8.63)3.09 (1.55–6.14)61.36 (0.63–2.93)1.29 (0.57–2.95)
CMF9661.08 (0.55–2.14)1.04 (0.51–2.12)31.21 (0.36–4.00)0.90 (0.27–3.04)21.11 (0.49–2.51)1.04 (0.46–2.36)
Hormone therapy
No.142489REF (1.00)REF (1.00)49REF (1.00)REF (1.00)43REF (1.00)REF (1.00)
Tamoxifen42472980.91 (0.72–1.15)0.95 (0.74–1.23)990.57 (0.41–0.79)0.84 (0.58–1.20)1420.91 (0.65–1.27)1.03 (0.71–1.48)
Aromatase inhibitors15501191.02 (0.77–1.35)0.99 (0.74–1.32)611.05 (0.71–1.56)1.08 (0.72–1.61)851.53 (1.05–2.24)1.52 (1.03–2.26)
Trastuzumab*
No.2137126REF (1.00)REF (1.00)38REF (1.00)REF (1.00)60REF (1.00)REF (1.00)
Yes304171.15 (0.70–1.92)1.50 (0.79–2.83)133.05 (1.62–5.76)2.34 (1.05–5.22)121.75 (0.94–3.27)1.83 (0.85–3.96)

  1. Total No. refers to the total number of patients. N events refers to the number of observed cases. HR = hazard ratio; CI = confidence interval; CMF = cyclophosphamide, methotrexate, and fluorouracil; REF: reference women in the matched controls from the general population. Hazard ratios are estimated from Cox proportional hazards models with time since diagnosis as underlying time scale. Hazard ratios for model 1 are adjusted for age and calendar period. Hazard ratios for model 2 are multivariable adjusted including age at diagnosis, year of diagnosis, menopausal status, Charlson comorbidity index, clinical stage, tumor size, type of surgery, history of hypertension, chronic pulmonary disease and tobacco abuse, and all treatment variables listed in the table.

  2. *

    Treatment-specific analysis of trastuzumab was restricted to patients diagnosed between 2005 and 2008.

Discussion

In a population-based setting, we demonstrated that the incidence of heart disease in breast cancer patients was significantly higher than the incidence observed in matched reference individuals from the general population. The risks of arrhythmia and heart failure were increased even beyond 10 years after diagnosis. Receipt of trastuzumab, as well as administration of anthracycline±taxane-based regimens, was independently associated with an increased risk of heart failure, while receipt of aromatase inhibitor therapy was associated with an increased risk of ischemic heart disease.

We found an increased risk of arrhythmia and heart failure in breast cancer patients as compared with the matched reference individuals from the general population, which is similar to the risk of heart failure reported by a previous Dutch study (Hooning et al., 2007), indicating the generalizability of our findings to European countries. However, as patients in our cohort were aged between 25 and 75 years, caution is needed when generalizing these findings to older patients, who may have more comorbidities.

Analysis by time since diagnosis revealed long-term increased risks of arrhythmia and heart failure following breast cancer diagnosis, suggesting that a longitudinal cardiac monitoring schedule might be helpful to improve cardiac health in breast cancer patients. As the long-term risk was observed for heart failure but not ischemic heart disease, the cardiotoxic effect of chemotherapy might be mainly on the myocardium mediated by the effect of DNA double-strand breaks through topoisomerase (Top) 2β, but not the cardiac vessels (Lyu et al., 2007). The finding that risk of ischemic heart disease in breast cancer patients was only transiently elevated after diagnosis is not unexpected, considering the emotional distress of dealing with a new cancer diagnosis in the patients, which may lead to higher short-term rates of ischemic heart disease (Fang et al., 2012; Schoormans et al., 2016). In addition, surgery after breast cancer diagnosis might increase the risk of arterial thromboembolism (Gervaso et al., 2021), which includes myocardial infarction, and the effect appears to attenuate 1 year after diagnosis (Navi et al., 2017; Navi et al., 2019). The long-term lower risk of ischemic heart disease in breast cancer patients compared to age-matched women might be explained by the opposite role of reproductive factors in breast cancer and ischemic heart disease. Women with younger age at menarche and older age at menopause were associated with increased risk of breast cancer, while decreased risk of ischemic heart disease were found among these women (Collaborative Group on Hormonal Factors in Breast, 2012; Okoth et al., 2020).

The findings that administration of anthracycline±taxanes, as well as trastuzumab, is associated with increased risks of heart failure are in agreement with previous observational studies (Bowles et al., 2012; Chavez-MacGregor et al., 2013; Doyle et al., 2005; Du et al., 2009; Goldhar et al., 2016; Thavendiranathan et al., 2016) and clinical trials (Chen et al., 2011) in specific subgroups of breast cancer patients. While (poly)chemotherapy is thought to lead to heart failure through a plethora of mechanisms that damage cardiomyocytes (Yeh and Bickford, 2009), taxanes may also interrupt the metabolism and excretion of anthracyclines, hence accentuating their toxicity (Bird and Swain, 2008). The cardiotoxic effect of trastuzumab meanwhile may be explained by inhibition of the HER-2 receptors in myocytes, which activates the mitochondrial apoptosis pathway through modulation of Bcl-xL and -xS, which regulates cell development and growth (Grazette et al., 2004; Yeh and Bickford, 2009). As there is no cardiac monitoring for chemotherapy in routine clinical practice and cardiac assessment is only performed prior to and during the treatment period for HER-2 positive patients in Sweden, a longer-term cardiac monitoring program might be helpful for these patients.

Population-based estimates of incidence of ischemic heart disease following treatment with aromatase inhibitors have not been extensively reported in the literature (Matthews et al., 2018). Abdel-Qadir et al. also found an increased risk of myocardial infarction in patients treated with aromatase inhibitors, as compared to those treated with tamoxifen (Abdel-Qadir et al., 2016). It has been posited that this apparent increase in risk of ischemic heart disease might in fact be attributed to reduced risk of heart disease following tamoxifen treatment (Hackshaw et al., 2011; Rosell et al., 2013). Nonetheless, given that in the present study, an increased risk of ischemic heart disease was observed in patients treated with aromatase inhibitors compared to patients not receiving hormone treatment, the protective effect from tamoxifen could not fully explain the previously reported risk increase of ischemic heart disease in patients treated with aromatase inhibitors.

While several previous studies have shown that radiotherapy for breast cancer increase the risk of ischemic heart disease and heart failure (Darby et al., 2013; Harris et al., 2006; Pinder et al., 2007), some studies, particularly those including patients diagnosed in recent decades, have not seen such an increase (Boekel et al., 2014; Wadsten et al., 2018; Wennstig et al., 2020). Indeed, the time trends of heart dose improvement and the use of modern heart dose sparing techniques, together with individualized doses of therapy, may result in lower doses of radiation to the heart (Taylor et al., 2017; Taylor and Kirby, 2015; Taylor et al., 2009). Another reason for inconsistent results in the literature could be that patients with a left-sided breast cancer who are susceptible to cardiovascular diseases are less likely to be selected for radiotherapy (Darby et al., 2013; Taylor and Kirby, 2015). Therefore, in our study, we compared risk of ischemic heart disease in patients treated with radiotherapy for left-sided to those treated for right-sided breast cancer. We found slightly increased non-significant risk of ischemic heart disease, this risk appeared (as expected) more pronounced in the follow-up period after 10 years. Overall, our results indicate only small risk of heart disease due to radiotherapy in women treated in Sweden after year 2000. Further studies with detailed information on the mean heart dose of radiation or total cumulative radiation dose administered are therefore needed to confirm and provide more context to this finding.

A major strength of our study is that we were able to investigate risks of heart disease by time since diagnosis and adjuvant treatment. The risk estimates presented in this study therefore provide an insight into the short-term and long-term effects of adjuvant breast cancer therapy in routine clinical practice. Notably, all breast cancer patients were followed-up for a relatively long period. The population-based nature of the study and linkage to registry-based data further minimized the risk of selection and information biases.

We acknowledge several limitations. The Swedish Patient Register has high validity for heart failure, arrhythmia, and ischemic heart disease (with positive predictive value between 88% and 98%) (Hammar et al., 2001; Ludvigsson et al., 2011), by analyzing main diagnoses only. However, misclassification of heart diseases may still have occurred. In addition, pre-existing comorbidities extracted from the patient register may not include those patients with mild symptoms. Second, we did not have complete data on trastuzumab during the study period and relied on HER-2 status as proxy, which may have resulted in some misclassification. The numbers of heart disease after treatment with trastuzumab and taxane were also relatively small in our study, and might have resulted in limited power or chance finding when identifying an association between trastuzumab/taxane and the relevant cardiac events. Besides, the Stockholm-Gotland Breast Cancer Register only records intended treatment, not whether patients actually received these therapies. However, the agreement between the intended and administered breast cancer treatment in Sweden has been previously reported to be about 95% (Löfgren et al., 2019). Finally, it should be noted that cancer patients are subject to increased medical surveillance, especially in the initial period after diagnosis. This could explain the increased rates of heart disease events especially within the first year of follow-up, although psychological distress following recent diagnosis with cancer represents an alternative plausible explanation for this observation (Fang et al., 2012; Schoormans et al., 2016).

Through this study, we demonstrate that compared to the general population, women with breast cancer have increased risks of heart disease including heart failure and arrhythmia. The short-term risk of ischemic heart disease diminished after 1 year post diagnosis. The increased risk of arrhythmia and heart failure however appears to persist long-term, beyond the first decade after diagnosis. Administration of systemic adjuvant therapies is associated with risks of heart disease. The risk estimates observed in this study may serve as reference to aid adjuvant therapy decision-making and patient counselling in oncology practices.

Appendix 1

Appendix 1—figure 1
Download asset Open asset
Flowchart of the data.

Appendix 2

Appendix 2—table 1
ICD codes used in the analyses.
Disease codesICD-10ICD-9
ArrhythmiaI47, I48, I49427
 Atrial fibrillationI48427D
 Tachycardia and other cardiac arrhythmiasI47, I49427A–C, 427E–J
Heart failureI50428A, 428B, 428X
Ischemic heart diseaseI20–I25410–414
 Myocardial infarctionI21, I22410
 Angina pectorisI20411B, 413, 414A
HypertensionI10–I15401–405
Tobacco abuse and Chronic Pulmonary DiseaseJ40–J47, J60–J67, F17, I278, I279, J684, J701, J703490–496,500–505, 416W, 416X, 506E, 508B, 508W, 305B

  1. ICD = International Classification of Diseases.

Appendix 2—table 2
Cumulative incidence estimates of heart diseases in breast cancer patients and age matched controls.
Cumulative incidence, % (95% CI)
6 months1 year2 years5 years10 years15 years
Arrhythmia
Breast cancer0.49 (0.35–0.66)0.81 (0.63–1.02)1.25 (1.02–1.52)2.77 (2.41–3.16)6.04 (5.49–6.63)11.03 (10.04–12.08)
Matched control0.20 (0.17–0.23)0.38 (0.34–0.42)0.79 (0.73–0.85)2.18 (2.08–2.29)4.98 (4.83–5.13)8.21 (7.99–8.45)
Heart failure
Breast cancer0.09 (0.04–0.18)0.28 (0.18–0.42)0.53 (0.38–0.71)1.06 (0.85–1.32)2.32 (1.98–2.70)4.80 (4.13–5.54)
Matched control0.05 (0.03–0.06)0.10 (0.08–0.13)0.22 (0.19–0.26)0.68 (0.63–0.74)1.87 (1.77–1.96)3.78 (3.62–3.95)
Ischemic heart disease
Breast cancer0.26 (0.17–0.40)0.48 (0.35–0.65)0.92 (0.73–1.16)1.93 (1.64–2.27)3.59 (3.17–4.05)5.68 (4.98–6.44)
Matched control0.13 (0.11–0.16)0.33 (0.29–0.37)0.72 (0.67–0.78)1.91 (1.81–2.00)3.85 (3.72–3.99)5.90 (5.71–6.09)

  1. Abbreviations: CI = confidence interval. Cumulative incidence estimates of heart diseases in all breast cancer patients (N = 8015) at different time-points following the index date ( = date of diagnosis in breast cancer patients). Cumulative incidence estimates are obtained from Aalen-Johansen estimation.

Appendix 2—table 3
Hazard ratios for heart diseases by different adjuvant therapies and time since diagnosis.
HR (95% CI) for arrhythmiaHR (95% CI) for heart failureHR (95% CI) for ischemic heart disease
Treatment variables<10 years>10 years<10 years>10 years<10 years>10 years
Radiotherapy
 Right-sidedREF (1.00)REF (1.00)REF (1.00)REF (1.00)REF (1.00)REF (1.00)
 Left-sided0.99 (0.79–1.24)0.80 (0.57–1.14)1.13 (0.77–1.66)0.94 (0.56–1.56)1.13 (0.84–1.53)1.29 (0.70–2.37)
 Both-sided0.26 (0.04–1.90)1.01 (0.30–3.36)1.49 (0.36–6.24)2.37 (0.54–10.41)0.84 (0.20–3.43)1.64 (0.21–12.89)
Chemotherapy
 NoREF (1.00)REF (1.00)REF (1.00)REF (1.00)REF (1.00)REF (1.00)
 Anthracyclines-based1.08 (0.81–1.46)1.07 (0.65–1.76)1.75 (1.11–2.76)1.66 (0.86–3.19)1.27 (0.87–1.85)1.36 (0.60–3.09)
 Anthracyclines + taxanes1.02 (0.51–2.01)0.87 (0.13–5.77)3.72 (1.72–8.03)0.00 (0.00–0.00)1.38 (0.60–3.18)0.00 (0.00–0.00)
 CMF1.24 (0.59–2.61)0.74 (0.18–3.15)1.16 (0.33–4.05)0.00 (0.00–0.00)0.97 (0.33–2.84)1.17 (0.16–8.41)
Hormone therapy
 NoREF (1.00)REF (1.00)REF (1.00)REF (1.00)REF (1.00)REF (1.00)
 Tamoxifen0.91 (0.67–1.23)1.08 (0.67–1.73)0.76 (0.49–1.20)0.98 (0.52–1.84)0.93 (0.62–1.39)1.50 (0.64–3.53)
 Aromatase inhibitors0.97 (0.70–1.36)1.05 (0.56–1.95)0.93 (0.58–1.49)1.47 (0.66–3.27)1.47 (0.96–2.24)1.31 (0.43–4.01)
Trastuzumab *
 NoREF (1.00)REF (1.00)REF (1.00)REF (1.00)REF (1.00)REF (1.00)
 Yes1.56 (0.82–2.97)0.00 (0.00–0.00)2.60 (1.14–5.89)0.00 (0.00–0.00)1.71 (0.76–3.87)6.95 (0.56–85.58)

  1. HR = hazard ratio; CI = confidence interval. Hazard ratios are estimated from Cox proportional hazards models with time since diagnosis as underlying time scale. Hazard ratios are multivariable adjusted including age at diagnosis, year of diagnosis, menopausal status, Charlson comorbidity index, clinical stage, type of surgery, hypertension, chronic pulmonary disease and tobacco abuse, and all treatment variables listed in the table. * Treatment-specific analysis of trastuzumab was restricted to patients diagnosed between 2005 and 2008.

Appendix 3

Appendix 3—figure 1
Download asset Open asset
Cumulative incidence of heart disease in breast cancer patients and matched women.

Aalen-Johansen estimates of the cumulative risk of heart disease by time since index date, in breast cancer patients and matched women from the general population. BC: breast cancer; REF: reference women in the matched controls from the general population; No.: number.

Data availability

The data used in this study are owned by the Swedish National Board of Health and Welfare and Statistics Sweden. According to Swedish law and GDPR, the authors are not able to make the dataset publicly available. Any researchers (including international researchers) interested in obtaining the data can do so by the following steps: (1) apply for ethical approval from their local ethical review boards; (2) contact the Swedish National Board of Health and Welfare and/or Statistics Sweden with the ethical approval and make a formal application of use of register data.

References

    1. Gray R
    2. Bradley R
    3. Braybrooke J
    4. Liu Z
    5. Peto R
    6. Davies L
    7. Dodwell D
    8. McGale P
    9. Pan H
    10. Taylor C
    11. Barlow W
    12. Bliss J
    13. Bruzzi P
    14. Cameron D
    15. Fountzilas G
    16. Loibl S
    17. Mackey J
    18. Martin M
    19. Del Mastro L
    20. Möbus V
    21. Nekljudova V
    22. De Placido S
    23. Swain S
    24. Untch M
    25. Pritchard KI
    26. Bergh J
    27. Norton L
    28. Boddington C
    29. Burrett J
    30. Clarke M
    31. Davies C
    32. Duane F
    33. Evans V
    34. Gettins L
    35. Godwin J
    36. Hills R
    37. James S
    38. Liu H
    39. MacKinnon E
    40. Mannu G
    41. McHugh T
    42. Morris P
    43. Read S
    44. Wang Y
    45. Wang Z
    46. Fasching P
    47. Harbeck N
    48. Piedbois P
    49. Gnant M
    50. Steger G
    51. Di Leo A
    52. Dolci S
    53. Francis P
    54. Larsimont D
    55. Nogaret JM
    56. Philippson C
    57. Piccart M
    58. Linn S
    59. Peer P
    60. Tjan-Heijnen V
    61. Vliek S
    62. Mackey J
    63. Slamon D
    64. Bartlett J
    65. Bramwell VH
    66. Chen B
    67. Chia S
    68. Gelmon K
    69. Goss P
    70. Levine M
    71. Parulekar W
    72. Pater J
    73. Rakovitch E
    74. Shepherd L
    75. Tu D
    76. Whelan T
    77. Berry D
    78. Broadwater G
    79. Cirrincione C
    80. Muss H
    81. Weiss R
    82. Shan Y
    83. Shao YF
    84. Wang X
    85. Xu B
    86. Zhao D-B
    87. Bartelink H
    88. Bijker N
    89. Bogaerts J
    90. Cardoso F
    91. Cufer T
    92. Julien J-P
    93. Poortmans P
    94. Rutgers E
    95. van de Velde C
    96. Carrasco E
    97. Segui MA
    98. Blohmer JU
    99. Costa S
    100. Gerber B
    101. Jackisch C
    102. von Minckwitz G
    103. Giuliano M
    104. De Laurentiis M
    105. Bamia C
    106. Koliou G-A
    107. Mavroudis D
    108. A’Hern R
    109. Ellis P
    110. Kilburn L
    111. Morden J
    112. Yarnold J
    113. Sadoon M
    114. Tulusan AH
    115. Anderson S
    116. Bass G
    117. Costantino J
    118. Dignam J
    119. Fisher B
    120. Geyer C
    121. Mamounas EP
    122. Paik S
    123. Redmond C
    124. Wickerham DL
    125. Venturini M
    126. Bighin C
    127. Pastorino S
    128. Pronzato P
    129. Sertoli MR
    130. Foukakis T
    131. Albain K
    132. Arriagada R
    133. Bergsten Nordström E
    134. Boccardo F
    135. Brain E
    136. Carey L
    137. Coates A
    138. Coleman R
    139. Correa C
    140. Cuzick J
    141. Davidson N
    142. Dowsett M
    143. Ewertz M
    144. Forbes J
    145. Gelber R
    146. Goldhirsch A
    147. Goodwin P
    148. Hayes D
    149. Hill C
    150. Ingle J
    151. Jagsi R
    152. Janni W
    153. Mukai H
    154. Ohashi Y
    155. Pierce L
    156. Raina V
    157. Ravdin P
    158. Rea D
    159. Regan M
    160. Robertson J
    161. Sparano J
    162. Tutt A
    163. Viale G
    164. Wilcken N
    165. Wolmark N
    166. Wood W
    167. Zambetti M
    (2019) Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials
    Lancet (London, England) 393:1440–1452.
    https://doi.org/10.1016/S0140-6736(18)33137-4
    1. Taylor CW
    2. Kirby AM
    (2015) Cardiac Side-effects From Breast Cancer Radiotherapy
    Clinical Oncology (Royal College of Radiologists (Great Britain)) 27:621–629.
    https://doi.org/10.1016/j.clon.2015.06.007

Article and author information

Author details

  1. Haomin Yang

    1. Department of Epidemiology and Health Statistics, School of Public Health, Fujian Medical University, Fuzhou, China
    2. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
    Contribution
    Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Validation, Visualization, Writing – original draft, Writing - review and editing
    For correspondence
    haomin.yang@ki.se
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2252-2606

  2. Nirmala Bhoo-Pathy

    Centre for Epidemiology and Evidence-Based Practice, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
    Contribution
    Conceptualization, Data curation, Formal analysis, Funding acquisition, Methodology, Project administration, Writing – original draft
    Competing interests
    received educational grants to their institution from Novartis, Pfizer, AIA Bhd and Pharmaceutical Association of Malaysia.Has received speaker's fees from Novartis, Pfizer and Roche, and received travel support from Roche and Pharmaceutical Association of Malaysia to attend conferences in 2018 and 2019. Has served on the advisory board of Pfizer Asia Pacific, Malaysia (2017/18 year), and been a committee member for Together Against Cancer (NGO) (2018 and 2019). Roche Diagnostics also provided Nirmala Bhoo-Pathy with research material, namely COVID-19 total antibody kits. The author has no other competing interests to declare
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0568-8863

  3. Judith S Brand

    Clinical Epidemiology and Biostatistics, School of Medical Sciences, Örebro University, Örebro, Sweden
    Contribution
    Conceptualization, Data curation, Formal analysis, Investigation, Resources, Software, Writing – original draft
    Competing interests
    No competing interests declared

  4. Elham Hedayati

    Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden
    Contribution
    Conceptualization, Methodology, Resources, Writing – original draft
    Competing interests
    No competing interests declared

  5. Felix Grassmann

    1. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
    2. Health and Medical University, Potsdam, Germany
    Contribution
    Formal analysis, Software, Writing – original draft
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1390-7528

  6. Erwei Zeng

    Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
    Contribution
    Formal analysis, Validation, Writing – original draft
    Competing interests
    No competing interests declared

  7. Jonas Bergh

    1. Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden
    2. Breast Cancer Center, Karolinska University Hospital, Stockholm, Sweden
    3. Karolinska Comprehensive Cancer Center, Stockholm, Sweden
    Contribution
    Conceptualization, Data curation, Supervision, Writing – original draft
    Competing interests
    research was supported by payments from Amgen, AstraZeneca, Bayer, Merck, Roche and Sanofi-Aventis to their institution, along with payments from non-profit organisations (Swedish Cancer Society and Knut Alice Wallenberg) and the Swedish Research Council. Also gave lectures to Astra Zeneca and Roche (no personal payment was received for these). Is a scientific advisor to The Medical product agency and to EMA, and is a representative of Swedish Breast Cancer Group. The author has no other competing interests to declare

  8. Weiwei Bian

    Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
    Contribution
    Data curation, Formal analysis, Validation, Writing – original draft
    Competing interests
    No competing interests declared

  9. Jonas F Ludvigsson

    1. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
    2. Department of Pediatrics, Örebro University Hospital, Örebro, Sweden
    Contribution
    Conceptualization, Supervision, Validation, Writing – original draft
    Competing interests
    coordinates a study on behalf of the Swedish IBD quality register (SWIBREG). This study has received funding from Janssen corporation. The author has no other competing interests to declare

  10. Per Hall

    1. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
    2. Department of Oncology, Södersjukhuset, Stockholm, Sweden
    Contribution
    Conceptualization, Data curation, Supervision, Writing – original draft
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5640-9126

  11. Kamila Czene

    Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
    Contribution
    Conceptualization, Data curation, Funding acquisition, Resources, Supervision, Writing – original draft, Writing - review and editing
    Competing interests
    No competing interests declared

Funding

Natural Science Foundation of Fujian Province (2021J01721)

  • Haomin Yang

Startup Fund for High-level Talents of Fujian Medical University (XRCZX2020007)

  • Haomin Yang

Startup Fund for Scientific Research, Fujian Medical University (2019QH1002)

  • Haomin Yang

Laboratory Construction Program of Fujian Medical University (1100160208)

  • Haomin Yang

Vetenskapsrådet (2018-02547)

  • Kamila Czene

Swedish Cancer Foundation (CAN-19-0266)

  • Kamila Czene

Forskningsrådet om Hälsa, Arbetsliv och Välfärd (2016-00081)

  • Kamila Czene

University of Malaya (Impact-Oriented Interdisciplinary Research Grant Programme IIRG006C-19HWB)

  • Nirmala Bhoo-Pathy

China Scholarship Council

  • Erwei Zeng

China Scholarship Council

  • Weiwei Bian

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Acknowledgements

Funding: This work was supported by the Swedish Research Council (grant no: 2018-02547); Swedish Cancer Society (grant no: CAN-19-0266); and FORTE (grant no: 2016-00081). HY was supported by Startup Fund for high-level talents of Fujian Medical University (grant no: XRCZX2020007) and Startup Fund for scientific research, Fujian Medical University (grant no: 2019QH1002). NBP was supported by the University of Malaya Impact-Oriented Interdisciplinary Research Grant Programme (grant no: IIRG006C-19HWB). EZ and WB was partly supported by China Scholarship council. Dr Ludvigsson coordinates a study on behalf of the Swedish IBD quality register (SWIBREG), which has received funding from Janssen corporation. The funders had no role in the study design, data collection, analyses, data interpretation, writing the manuscript, or in the decision to submit the manuscript for publication.

Ethics

Human subjects: The study was approved by the Regional Ethical Review Board in Stockholm (Dnr 2009/254-31/4). In accordance with their decision, it was not necessary to obtain informed consent from participants involved in the study. All individuals' information was anonymized and de-identified prior to analysis.

Version history

  1. Received: June 23, 2021
  2. Preprint posted: September 21, 2021 (view preprint)
  3. Accepted: March 8, 2022
  4. Accepted Manuscript published: March 16, 2022 (version 1)
  5. Version of Record published: March 22, 2022 (version 2)

Copyright

© 2022, Yang et al.

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,266
    views
  • 280
    downloads
  • 11
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Haomin Yang
  2. Nirmala Bhoo-Pathy
  3. Judith S Brand
  4. Elham Hedayati
  5. Felix Grassmann
  6. Erwei Zeng
  7. Jonas Bergh
  8. Weiwei Bian
  9. Jonas F Ludvigsson
  10. Per Hall
  11. Kamila Czene
(2022)
Risk of heart disease following treatment for breast cancer – results from a population-based cohort study
eLife 11:e71562.
https://doi.org/10.7554/eLife.71562

Share this article

https://doi.org/10.7554/eLife.71562

Categories and tags

Research organism

Further reading

    1. Epidemiology and Global Health

    A retrospective cohort study of Paxlovid efficacy depending on treatment time in hospitalized COVID-19 patients

    Zhanwei Du, Lin Wang ... Lauren A Meyers
    Short Report

    Paxlovid, a SARS-CoV-2 antiviral, not only prevents severe illness but also curtails viral shedding, lowering transmission risks from treated patients. By fitting a mathematical model of within-host Omicron viral dynamics to electronic health records data from 208 hospitalized patients in Hong Kong, we estimate that Paxlovid can inhibit over 90% of viral replication. However, its effectiveness critically depends on the timing of treatment. If treatment is initiated three days after symptoms first appear, we estimate a 17% chance of a post-treatment viral rebound and a 12% (95% CI: 0%-16%) reduction in overall infectiousness for non-rebound cases. Earlier treatment significantly elevates the risk of rebound without further reducing infectiousness, whereas starting beyond five days reduces its efficacy in curbing peak viral shedding. Among the 104 patients who received Paxlovid, 62% began treatment within an optimal three-to-five-day day window after symptoms appeared. Our findings indicate that broader global access to Paxlovid, coupled with appropriately timed treatment, can mitigate the severity and transmission of SARS-Cov-2.

    1. Epidemiology and Global Health

    Higher ratio of plasma omega-6/omega-3 fatty acids is associated with greater risk of all-cause, cancer, and cardiovascular mortality: A population-based cohort study in UK Biobank

    Yuchen Zhang, Yitang Sun ... Kaixiong Ye
    Research Article

    Background:

    Circulating omega-3 and omega-6 polyunsaturated fatty acids (PUFAs) have been associated with various chronic diseases and mortality, but results are conflicting. Few studies examined the role of omega-6/omega-3 ratio in mortality.

    Methods:

    We investigated plasma omega-3 and omega-6 PUFAs and their ratio in relation to all-cause and cause-specific mortality in a large prospective cohort, the UK Biobank. Of 85,425 participants who had complete information on circulating PUFAs, 6461 died during follow-up, including 2794 from cancer and 1668 from cardiovascular disease (CVD). Associations were estimated by multivariable Cox proportional hazards regression with adjustment for relevant risk factors.

    Results:

    Risk for all three mortality outcomes increased as the ratio of omega-6/omega-3 PUFAs increased (all Ptrend <0.05). Comparing the highest to the lowest quintiles, individuals had 26% (95% CI, 15–38%) higher total mortality, 14% (95% CI, 0–31%) higher cancer mortality, and 31% (95% CI, 10–55%) higher CVD mortality. Moreover, omega-3 and omega-6 PUFAs in plasma were all inversely associated with all-cause, cancer, and CVD mortality, with omega-3 showing stronger effects.

    Conclusions:

    Using a population-based cohort in UK Biobank, our study revealed a strong association between the ratio of circulating omega-6/omega-3 PUFAs and the risk of all-cause, cancer, and CVD mortality.

    Funding:

    Research reported in this publication was supported by the National Institute of General Medical Sciences of the National Institute of Health under the award number R35GM143060 (KY). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

    1. Ecology
    2. Epidemiology and Global Health

    Exploring factors shaping antibiotic resistance patterns in Streptococcus pneumoniae during the 2020 COVID-19 pandemic

    Aleksandra Kovacevic, David RM Smith ... Lulla Opatowski
    Research Article

    Non-pharmaceutical interventions implemented to block SARS-CoV-2 transmission in early 2020 led to global reductions in the incidence of invasive pneumococcal disease (IPD). By contrast, most European countries reported an increase in antibiotic resistance among invasive Streptococcus pneumoniae isolates from 2019 to 2020, while an increasing number of studies reported stable pneumococcal carriage prevalence over the same period. To disentangle the impacts of the COVID-19 pandemic on pneumococcal epidemiology in the community setting, we propose a mathematical model formalizing simultaneous transmission of SARS-CoV-2 and antibiotic-sensitive and -resistant strains of S. pneumoniae. To test hypotheses underlying these trends five mechanisms were built into the model and examined: (1) a population-wide reduction of antibiotic prescriptions in the community, (2) lockdown effect on pneumococcal transmission, (3) a reduced risk of developing an IPD due to the absence of common respiratory viruses, (4) community azithromycin use in COVID-19 infected individuals, (5) and a longer carriage duration of antibiotic-resistant pneumococcal strains. Among 31 possible pandemic scenarios involving mechanisms individually or in combination, model simulations surprisingly identified only two scenarios that reproduced the reported trends in the general population. They included factors (1), (3), and (4). These scenarios replicated a nearly 50% reduction in annual IPD, and an increase in antibiotic resistance from 20% to 22%, all while maintaining a relatively stable pneumococcal carriage. Exploring further, higher SARS-CoV-2 R0 values and synergistic within-host virus-bacteria interaction mechanisms could have additionally contributed to the observed antibiotic resistance increase. Our work demonstrates the utility of the mathematical modeling approach in unraveling the complex effects of the COVID-19 pandemic responses on AMR dynamics.